Acura Pharmaceuticals (ACUR) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 12, 2021
Document And Entity Information
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Entity Registrant Name	Acura Pharmaceuticals, Inc
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-10113
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	11-0853640
Entity Address, Address Line One	616 N. North Court, Suite 120,
Entity Address, City or Town	Palatine
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60067
City Area Code	847
Local Phone Number	705-7709
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ACUR
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		65,089,043
Entity Central Index Key	0000786947
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets:
Cash	$ 89	$ 413
Royalty receivable	67	30
Collaboration revenue receivable from related party	73	197
License fee revenue receivable from related party	400	400
Prepaid expenses and other current assets	216	139
Total current assets	845	1,179
Finance lease right of use (Note 11)	59	0
Property, plant and equipment, net (Note 5)	449	484
Intangible asset, net (Note 2)	53	73
Total assets	1,406	1,736
Liabilities:
Accounts payable	135	31
Accrued expenses (Note 6)	771	631
Finance lease liability - current	33	0
Loans under CARES Act	0	164
Other current liabilities (Note 10)	41	18
Accrued interest to related party (Note 7)	0	678
Convertible debt to related party, net of discounts (Note 7)	0	6,000
Total current liabilities	980	7,522
Finance lease liability - noncurrent	25	0
Loans under CARES Act - noncurrent	266	105
Total liabilities	1,271	7,627
Commitments and contingencies (Note 11)
Stockholders' equity (deficit):
Common stock - $0.01 par value per share; 100,000 shares authorized, 65,089 and 21,650 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	651	216
Additional paid-in capital	389,596	383,097
Accumulated deficit	(390,112)	(389,204)
Total stockholders' equity (deficit)	135	(5,891)
Total liabilities and stockholders' equity (deficit)	$ 1,406	$ 1,736

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares shares in Thousands	Sep. 30, 2021	Dec. 31, 2020
CONSOLIDATED BALANCE SHEETS
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	65,089	21,650
Common stock, shares outstanding	65,089	21,650

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Royalties	$ 67	$ 14	$ 102	$ 81
Collaboration - related party	3	96	25	148
License fees - related party	200	300	1,400	2,400
Product sales, net of allowance (Note 3)	0		0	223
Total revenues	270	410	1,527	2,852
Expenses:
Research and development	385	519	1,180	1,351
General and administrative	416	456	1,324	2,128
Total expenses	801	975	2,504	3,479
Operating loss	(531)	(565)	(977)	(627)
Gain on forgiveness of a loan under CARES Act (Note 7)	269	0	269	0
Interest expense - related party (Note 7)	0	(113)	(200)	(338)
Loss before provision for income taxes	(262)	(678)	(908)	(965)
Provision for income taxes	0	0	0	0
Net loss	$ (262)	$ (678)	$ (908)	$ (965)
Net income (loss) per share:
Basic	$ 0	$ (0.02)	$ (0.02)	$ (0.03)
Diluted	$ 0	$ (0.02)	$ (0.02)	$ (0.03)
Weighted average number of shares outstanding:
Basic	75,561	32,336	50,464	32,304
Diluted	75,561	32,336	50,464	32,304

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional paid-in capital	Accumulated deficit	Total
Balance at Dec. 31, 2019	$ 213	$ 383,042	$ (387,996)	$ (4,741)
Balance (in shares) at Dec. 31, 2019	21,300
Net (loss) income			(595)	(595)
Non-cash stock-based compensation		9		9
Net distribution of common stock pursuant to restricted stock unit award plan	$ 3	19		22
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	350
Balance at Mar. 31, 2020	$ 216	383,070	(388,591)	(5,305)
Balance (in shares) at Mar. 31, 2020	21,650
Balance at Dec. 31, 2019	$ 213	383,042	(387,996)	(4,741)
Balance (in shares) at Dec. 31, 2019	21,300
Net (loss) income				(965)
Balance at Sep. 30, 2020	$ 216	383,088	(388,961)	(5,657)
Balance (in shares) at Sep. 30, 2020	21,650
Balance at Mar. 31, 2020	$ 216	383,070	(388,591)	(5,305)
Balance (in shares) at Mar. 31, 2020	21,650
Net (loss) income			308	308
Non-cash stock-based compensation		9		9
Balance at Jun. 30, 2020	$ 216	383,079	(388,283)	(4,988)
Balance (in shares) at Jun. 30, 2020	21,650
Net (loss) income			(678)	(678)
Non-cash stock-based compensation		9		9
Balance at Sep. 30, 2020	$ 216	383,088	(388,961)	(5,657)
Balance (in shares) at Sep. 30, 2020	21,650
Balance at Dec. 31, 2020	$ 216	383,097	(389,204)	(5,891)
Balance (in shares) at Dec. 31, 2020	21,650
Net (loss) income			(259)	(259)
Net distribution of common stock pursuant to restricted stock unit award plan	$ 4	9		13
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	405
Exercise of stock options	$ 1	(1)
Exercise of stock options (in shares)	50
Balance at Mar. 31, 2021	$ 221	383,105	(389,463)	(6,137)
Balance (in shares) at Mar. 31, 2021	22,105
Balance at Dec. 31, 2020	$ 216	383,097	(389,204)	(5,891)
Balance (in shares) at Dec. 31, 2020	21,650
Net (loss) income				(908)
Balance at Sep. 30, 2021	$ 651	389,596	(390,112)	135
Balance (in shares) at Sep. 30, 2021	65,089
Balance at Mar. 31, 2021	$ 221	383,105	(389,463)	(6,137)
Balance (in shares) at Mar. 31, 2021	22,105
Net (loss) income			(387)	(387)
Non-cash stock-based compensation		29		29
Conversion of debt principal	$ 375	5,625		6,000
Conversion of debt principal(In shares)	37,500
Conversion of debt interest	$ 55	822		877
Conversion of debt interest(in shares)	5,484
Balance at Jun. 30, 2021	$ 651	389,581	(389,850)	382
Balance (in shares) at Jun. 30, 2021	65,089
Net (loss) income			(262)	(262)
Non-cash stock-based compensation		15		15
Balance at Sep. 30, 2021	$ 651	$ 389,596	$ (390,112)	$ 135
Balance (in shares) at Sep. 30, 2021	65,089

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash Flows from Operating Activities:
Net loss	$ (908)	$ (965)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	35	42
Non-cash stock-based compensation	44	27
Amortization of intangible asset	20	64
Amortization of right of use asset	8	0
Impairment charge on intangible asset	0	668
Changes in assets and liabilities:
Royalty receivable	(37)	75
Collaboration revenue receivable from related party	124	(37)
License fee receivable from related party	0	(800)
Prepaid expenses and other current assets	(77)	(86)
Income taxes refundable	0	67
Accounts payable	104	47
Accrued expenses	140	136
Lease liability	(8)	0
Sales return liability	0	(223)
Accrued interest on related party loans	199	338
Other current liabilities	40	8
Net cash used in operating activities	(316)	(639)
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	3	3
Statutory minimum payroll withholding taxes paid on the distribution of shares under a RSU award plan	(8)	(2)
Proceeds from loan under CARES Act	266	269
Gain on forgiveness of a loan under CARES Act	(269)	0
Net cash (used in) provided by financing activities	(8)	270
Net decrease in cash	(324)	(369)
Cash at beginning of period	413	862
Cash at end of end of period	89	493
Supplemental Disclosures of Cash Flow Information:
Cash paid for income taxes	0	0
Cash paid for interest	$ 0	$ 0

OPERATIONS AND SUMMARY OF SIGNI

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principal Operations Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is being developed to minimize the risk of overdose, our Aversion® Technology is intended to address methods of abuse associated with opioid analgesics while our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine , or PSE, into methamphetamine. Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Nexafed brand products utilize our Impede Technology. ● Limitx, a development stage technology, is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. The exclusive commercialization rights in the United States to LTX-03 as well as to LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam) are licensed to Abuse Deterrent Pharma, LLC (“AD Pharma”) (See Note 2). ● Our Aversion Technology has been licensed to Assertio Holdings Inc. for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths (See Note 2). ● Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC (MainPointe), our Impede Technology in the United States and Canada to commercialize these Nexafed products (See Note 2). Basis of Presentation, Liquidity and Substantial Doubt of Going Concern The accompanying consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern in accordance with generally accepted accounting principles in the United States of America. The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of September 30, 2021, we had cash of $89 thousand, working capital deficit of $135 thousand and an accumulated deficit of $390 million. We had a loss from operations of $977 thousand and a net loss of $908 thousand for the nine months ended September 30, 2021, and had a loss from operations of $758 thousand and a net loss of $1.2 million for the year ended December 31, 2020. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We anticipate operating losses to continue for the foreseeable future. On June 28, 2019 we announced a License, Development and Commercialization Agreement, as amended in October 2020 and in July 2021 (the “AD Pharma Amended Agreement”), with Abuse Deterrent Pharma, LLC (“AD Pharma”). The AD Pharma Amended Agreement required AD Pharma to pay us a monthly license payment of $350 thousand for a period from inception up to April 2020 at which time the payment became $200 thousand per month and continued through July 31, 2021, and to reimburse us all our outside development costs for LTX-03. At September 30, 2021, AD Pharma was delinquent in remitting the monthly license payments to us for June, 2021 and July, 2021 which aggregates to $400 thousand, and approximately $72 thousand of reimbursable LTX-03 development expenses. Failure to make these payments is an event of default under the AD Pharma Amended Agreement. In October and November 2021, AD Pharma remitted to us $350 thousand of the $400 thousand license fees. The AD Pharma Amended Agreement, requires the NDA for LTX-03 be accepted by the FDA by February 28, 2022 or AD Pharma has the option to terminate the AD Pharma Amended Agreement and take ownership of the LIMITx intellectual property. The AD Pharma Amended Agreement allows AD Pharma to terminate the AD Pharma Amended Agreement “for convenience”.Whether or not AD Pharma exercises their right to terminate the AD Pharma Amended Agreement, we need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Our future sources of revenue, if any, will be derived from licensing fees, milestone payments and royalties under the AD Pharma Amended Agreement, the Assertio Agreement, the MainPointe Agreement and similar agreements which we may enter into for our LIMITx products in development with other pharmaceutical company partners, for which there can be no assurance. The amount and timing of our future cash requirements will depend on regulatory and market acceptance of our product candidates and the resources we devote to the development and commercialization of our product candidates. COVID-19 On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic (“coronavirus pandemic”), based on the rapid increase in exposure globally. The coronavirus pandemic continues to affect the United States and global economies. If the outbreak continues, it may affect the Company’s operations and those of third parties on which the Company relies, including causing disruptions in the supply of the Company’s product candidates and the conduct of current and planned preclinical and clinical studies and contract manufacturing operations. We may need to limit operations or implement limitations, and may experience limitations in employee resources. The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions by government authorities to contain the outbreak or treat its impact, the emergence of new COVID-19 variants, and the related potential for new surges in infections, and the distribution, public acceptance and efficacy of COVID-19 vaccines including for emerging variants. Additionally, while the potential economic impact brought by, and the duration of, the coronavirus pandemic is difficult to assess or predict, the impact of the coronavirus on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact the Company’s short-term and long-term liquidity and the Company’s ability to complete its preclinical studies on a timely basis, or at all. The ultimate impact of coronavirus is highly uncertain and subject to change. The Company does not yet know the full extent of potential delays or impacts on its business, financing, preclinical and clinical trial activities, contract manufacturing operations or the global economy as a whole. However, these effects could have a material, adverse impact on the Company’s liquidity, capital resources, operations and business and those of the third parties on which we rely.

LICENSE AND COLLABORATION AGREE

LICENSE AND COLLABORATION AGREEMENTS	9 Months Ended
	Sep. 30, 2021
LICENSE AND COLLABORATION AGREEMENTS
LICENSE AND COLLABORATION AGREEMENTS	NOTE 2 – LICENSE AND COLLABORATION AGREEMENTS The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement. AD Pharma Agreement covering LTX-03 On June 28, 2019 we announced a License, Development and Commercialization Agreement, as amended in October 2020 and in July 2021 (the “AD Pharma Amended Agreement”), with Abuse Deterrent Pharma, LLC (“AD Pharma”), The AD Pharma Amended Agreement required AD Pharma to pay us a monthly license payment of $350 thousand for a period from inception up to April 2020 at which time the payment became $200 thousand per month and ended on July 31, 2021, and to reimburse us all our outside development costs for LTX-03. At September 30, 2021, AD Pharma was delinquent in remitting the monthly license payments to us for June, 2021 and July, 2021 which aggregates to $400 thousand, and approximately $72 thousand of reimbursable LTX-03 development expenses. Failure to make these payments is an event of default under the AD Pharma Amended Agreement. In October and November 2021, AD Pharma remitted to us $350 thousand of the $400 thousand license fees. The AD Pharma Amended Agreement, requires the NDA for LTX-03 be accepted by the FDA by February 28, 2022 or AD Pharma has the option to terminate the AD Pharma Amended Agreement and take ownership of the LIMITx intellectual property. Should AD Pharma choose not to exercise this option to terminate and the NDA for LTX-03 is subsequently accepted by the FDA, such option expires. AD Pharma does have the right to terminate the AD Pharma Amended Agreement anytime for “convenience on 30 days prior written notice”. AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones. AD Pharma also has a license to the Limitx patents for LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam) which are not subject to any development agreement or responsibilities by Acura. We had also previously granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength, and the Option Product exercise price of $500 thousand was waived if the exercise of the option occurred by June 28, 2024 (five years from the effective date). Effective with the October 2020 amendment, this option and right was rescinded. Assertio Agreement covering Oxaydo In April 2014, we terminated an agreement with Pfizer which resulted in the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the Pfizer agreement was terminated. As of September 30, 2021, the remaining useful life is 24 months or 2.0 years. The recoverability of the Aversion intangible asset is contingent upon future Assertio royalty revenues to us under a license agreement with them. During the first quarter 2020 a triggering event occurred with the decline in royalty cash flows from Assertio, and we performed an impairment test which indicated that the carrying value of the intangible asset was greater than the fair value. The impairment test resulted in a $668 thousand impairment charge against the intangible asset, which was determined using our estimate of discounted royalty cash flows remaining under our license agreement with Assertio, and recorded a like amount to general and administrative expense. We have recorded amortization expense of $20 thousand and $64 thousand in each of the nine month periods ending September 30, 2021 and 2020, respectively. Amortization of the patent for its remaining useful life is expected to approximate $6 thousand per quarter. The Aversion intangible asset is summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Intangible asset – Aversion ​ 2,000 ​ 2,000 Less: accumulated amortization ​ (1,279) ​ (1,259) Less: reserve for impairment ​ (668) ​ (668) Net ​ $ 53 ​ $ 73 ​ In January 2015, we and Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (now known as Assertio Holdings Inc. and formerly known as Zyla Life Sciences), or collectively Assertio, entered into a Collaboration and License Agreement (the “Assertio Agreement”) to commercialize Aversion Oxycodone under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Assertio Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Assertio and Assertio is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. Assertio paid us a $5.0 million license fee upon signing of the Assertio Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We are entitled to receive from Assertio a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). Assertio’s royalty payment obligations commenced on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Assertio to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor. As part of a 2020 restructuring by Assertio, it is our understanding that they have decided to reduce selling efforts pertaining to Oxaydo and as such, we expect royalties to decline over the remainder of the Agreement. The Assertio Agreement expires upon the expiration of Assertio’s royalty payment obligations in all countries. MainPointe Agreement covering Nexafed Products In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede Technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® Technology for products covered by the Agreement in such country. MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede Technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength and the Option Product exercise price of $500 thousand was waived if the exercise of the option occurred by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). Effective with the October 2020 amendment, this option and right was rescinded. The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede Technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. On January 1, 2020, MainPointe assigned to AD Pharma, with Acura’s consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura; which was rescinded by AD Pharma in October 2020. KemPharm Agreement Covering Certain Opioid Prodrugs In October 2016, we and KemPharm Inc. (“KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® Technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion Technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion Technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion Technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion Technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free. The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

REVENUE FROM CONTRACTS WITH CUS

REVENUE FROM CONTRACTS WITH CUSTOMERS	9 Months Ended
	Sep. 30, 2021
REVENUE FROM CONTRACTS WITH CUSTOMERS
REVENUE FROM CONTRACTS WITH CUSTOMERS	NOTE 3 – REVENUE FROM CONTRACTS WITH CUSTOMERS Revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at either September 30, 2021 or December 31, 2020. The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation. The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract. Price adjustments are accounted for as variable consideration. Provisions for variable consideration are based on current assumptions, executed contracts, and historical data and are provided for in the period the related revenues are recorded. Sales-based Milestones and Royalty Revenues The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Assertio and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter. License and Collaboration Agreement Revenues The achievement of milestones under the Company’s license and collaboration agreements will be recorded as revenue during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded as revenue when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled. The monthly license fee under the Company’s LTX-03 license and collaboration agreement will be recorded as revenue upon the fulfillment of the monthly development activities. The out-of-pocket development expenses under the license and collaboration agreements will be recorded as revenue upon the performance of the service or delivery of the material during the month. On June 28, 2019 we announced a License, Development and Commercialization Agreement, as amended in October 2020 and in July 2021 (the “AD Pharma Amended Agreement”), with Abuse Deterrent Pharma, LLC (“AD Pharma”), The AD Pharma Amended Agreement required AD Pharma to pay us a monthly license payment of $350 thousand for a period from inception up to April 2020 at which time the payment became $200 thousand per month and ended on July 31, 2021, and to reimburse us all our outside development costs for LTX-03. At September 30, 2021, AD Pharma was delinquent in remitting the monthly license payments to us for June, 2021 and July, 2021 which aggregates to $400 thousand, and approximately $72 thousand of reimbursable LTX-03 development expenses. Failure to make these payments is an event of default under the AD Pharma Amended Agreement. In October and November 2021, AD Pharma remitted to us $350 thousand of the $400 thousand license fees. The AD Pharma Amended Agreement, requires the NDA for LTX-03 be accepted by the FDA by February 28, 2022 or AD Pharma has the option to terminate the AD Pharma Amended Agreement and take ownership of the LIMITx intellectual property. The AD Pharma Amended Agreement allows AD Pharma to terminate the AD Pharma Amended Agreement “for convenience”. Product Sales, net of allowance Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. Prior to entering into the MainPointe Agreement in March 2017, we sold our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products were sold Disaggregation of Total Revenues The Company has two license agreements for currently marketed products containing its technologies; the Oxaydo product containing the Aversion Technology has been licensed to Assertio and the Nexafed products containing the Impede Technology which have been licensed to MainPointe. The Company has a third license agreement, having a product under development, LTX-03, containing its LIMITx™ technology, with AD Pharma. We have recorded $0.2 million and $0.3 million of license fees for LTX-03 during the three months ended September 30, 2021 and 2020, respectively. We have recorded $1.4 million and $2.4 million of license fees for LTX-03 during the nine months ended September 30, 2021 and 2020, respectively. On January 1, 2020, MainPointe assigned to AD Pharma, with Acura’s consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura; which was rescinded by AD Pharma in October 2020. All of the Company’s royalty revenues are earned from these two license agreements by the licensee’s sale of products in the United States. Royalty revenues by licensee are summarized below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Assertio (Oxaydo) ​ $ 67 ​ $ 11 ​ $ 100 ​ $ 72 MainPointe - related party (Nexafed) ​ — ​ 3 ​ ​ 2 ​ ​ 9 Royalty revenues ​ $ 67 ​ $ 14 ​ $ 102 ​ $ 81 ​ Contract Balance and Performance Obligations The Company had no contract assets and contract liability balances under the license and collaboration agreements at either September 30, 2021 or 2020. Contract assets may be reported in future periods under prepaid expenses or other current assets on the consolidated balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the consolidated balance sheet.

RESEARCH AND DEVELOPMENT

RESEARCH AND DEVELOPMENT	9 Months Ended
	Sep. 30, 2021
RESEARCH AND DEVELOPMENT
RESEARCH AND DEVELOPMENT	NOTE 4 – RESEARCH AND DEVELOPMENT Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and stock-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to the CRO’s based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the consolidated financial statements as prepaid expenses. We review and charge to expense accrued CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Our accrued CRO costs are subject to revisions as such studies progress towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have prepaid CRO costs or prepaid clinical trial study expenses at September 30, 2021 or 2020.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2021
PROPERTY, PLANT AND EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT	NOTE 5 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment is summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2021 2020 ​ ​ (in thousands) Building and improvements ​ $ 1,273 ​ $ 1,273 Scientific equipment ​ 597 ​ 597 Computer hardware and software ​ 104 ​ 106 Machinery and equipment ​ 274 ​ 274 Land and improvements ​ 162 ​ 162 Other personal property ​ 69 ​ 70 Office equipment ​ 27 ​ 27 Total ​ 2,506 ​ 2,509 Less: accumulated depreciation ​ (2,057) ​ (2,025) Net property, plant and equipment ​ $ 449 ​ $ 484 ​ We do not have leasehold improvements. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts. Depreciation expense was $12 thousand and $13 thousand for each of the three month periods ended September 30, 2021 and 2020, respectively. Depreciation expense was $35 thousand and $42 thousand for each of the nine month periods ended September 30, 2021 and 2020, respectively.

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Sep. 30, 2021
ACCRUED EXPENSES
ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2021 2020 ​ ​ (in thousands) Cost sharing expenses under license agreements ​ $ 428 ​ $ 428 Other fees and services ​ 26 ​ 24 Payroll, payroll taxes and benefits ​ 39 ​ 8 Professional services ​ 157 ​ 117 Financed premiums on insurance policies ​ 83 ​ 28 Property taxes ​ 7 ​ 9 Franchise taxes ​ 31 ​ 17 Total ​ $ 771 ​ $ 631 ​

DEBT

DEBT	9 Months Ended
	Sep. 30, 2021
DEBT
DEBT	NOTE 7 – DEBT Related Party Convertible Loan At December 31, 2018, we had borrowed an aggregate of $4.35 million from Mr. Schutte, a related-party. From January 1, 2019 and through June 27, 2019, we borrowed additional amounts from Mr. Schutte for $650 thousand and issued various promissory notes to him with the same terms and conditions from the previous loans (the Schutte Notes).On June 28, 2019 we restructured the $5.0 million loan to borrow an additional $725 thousand from Mr. Schutte bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted principal and interest conversion rights into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the loan is convertible into 37.5 million shares of our common stock. The $6.0 million convertible debt, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. Interest expense was $113 thousand for the three month period ended September 30, 2020, and was $200 thousand and $338 thousand for each of the nine month periods ended September 30, 2021 and 2020, respectively. On June 9, 2021, we received notice of conversion from AD Pharma for the $6.0 million Promissory Note and approximately $877 thousand of accrued but unpaid interest. The principal and interest were converted into 42,984,375 shares of the Company’s common stock. Effective with this conversion, the Promissory Note is retired and the Company is working with AD Pharma to release their security interest in all the Company’s assets. AD Pharma directly owns approximately 66% of our common stock at September 30, 2021. Paycheck Protection Program 1 st PPP Loan On April 13, 2020, the Company received a loan (the “1 st st 2 nd PPP Loan On March 16, 2021, the Company received a loan (the “2 nd nd nd

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS In July 2017, we completed a $4.0 million private placement with Mr. Schutte, consisting of 8,912,655 units (“Units”) of the Company, at a price of $0.4488 per Unit (the “Transaction”). Each Unit consists of one share of common stock and a warrant to purchase one fifth (0.2) of a share of common stock. The issue price of the Units was equal to 85% of the average last sale price of our common stock for the five trading days prior to completion of the Transaction. The warrants are immediately exercisable for 1,782,532 common shares at a price of $0.528 per share (which equals the average last sale price of the Company’s common stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. As part of the closing of the Transaction, the Company and Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for Mr. Schutte to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Mr. Schutte, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Mr. Schutte to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our common stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Mr. Schutte has not designated a director as of the date of filing of this Report on Form 10-Q. Galen had not designated a director and lost that right in December 2017 when it disposed of its shares of common stock in the Company. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. An independent director has not been named to fill the seat forfeited by Galen. MainPointe Pharmaceuticals LLC Mr. Schutte is the principal owner of MainPointe Pharmaceuticals LLC, a Kentucky limited liability company (“MainPointe”). In March 2017, we granted MainPointe an exclusive license to our Impede Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million. The Company is receiving a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported royalty revenue for the three months ended September 30, 2021 and 2020 is $0 thousand and $3 thousand, respectively of royalty revenue from MainPointe. Included in the reported royalty revenue for the nine months ended September 30, 2021 and 2020 is $2 thousand and $9 thousand, respectively of royalty revenue from MainPointe. (See Note 2). On January 1, 2020, MainPointe assigned to AD Pharma, with Acura’s consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura; which was rescinded by AD Pharma in October 2020. Loans with Mr. John Schutte At December 31, 2018, we had borrowed an aggregate of $4.35 million from Mr. Schutte, a related-party. During the period January 1, 2019 through June 27, 2019 we borrowed an aggregate of $650 thousand from Mr. Schutte. On June 28, 2019 we borrowed an additional $725 thousand from Mr. Schutte, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted conversion rights of principal and interest into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the note is convertible into 37.5 million shares of our common stock. The $6.0 million convertible debt, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. On June 9, 2021, we received notice of conversion from AD Pharma for the $6.0 million Promissory Note and approximately $877 thousand of accrued but unpaid interest. The principal and interest were converted into 42,984,375 shares of the Company’s common stock. Effective with this conversion, the Promissory Note is retired and the Company is working with AD Pharma, LLC to release their security interest in all the Company’s assets. AD Pharma directly owns approximately 66% of our common stock at September 30, 2021. AD Pharma Agreement covering LTX-03 On June 28, 2019 we entered into a License, Development and Commercialization Agreement, as amended in October 2020 and in July 2021 (the “AD Pharma Amended Agreement”), with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors for the completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The AD Pharma Amended Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03 as well as LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam). The AD Pharma Amended Agreement required AD Pharma to pay us a monthly license payment of $350 thousand for a period from inception up to April 2020 at which time the payment became $200 thousand per month and ended on July 31, 2021, and to reimburse us all our outside development costs for LTX-03. At September 30, 2021, AD Pharma was delinquent in remitting the monthly license payments to us for June, 2021 and July, 2021 which aggregates to $400 thousand, and approximately $72 thousand of reimbursable LTX-03 development expenses. Failure to make these payments is an event of default under the AD Pharma Amended Agreement. In October and November 2021, AD Pharma remitted to us $350 thousand of the $400 thousand license fees. The AD Pharma Amended Agreement, requires the NDA for LTX-03 be accepted by the FDA by February 28, 2022 or AD Pharma has the option to terminate the AD Pharma Amended Agreement and take ownership of the LIMITx intellectual property. Should AD Pharma choose not to exercise this option to terminate and the NDA for LTX-03 is subsequently accepted by the FDA, such option expires. AD Pharma does have the right to terminate the AD Pharma Amended Agreement anytime for “convenience on 30 days prior written notice”. AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones. AD Pharma also has a license to the Limitx patents for LTX-02 (oxycodone/acetaminophen) and LTX-09 (alprazolam) which are not subject to any development agreement or responsibilities by Acura. Upon commercialization of the licensed products, Acura receives stepped royalties on sales and is eligible for certain sales related milestones. We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength), and the Option Product exercise price of $500 thousand was waived if the exercise of the option occurred by June 28, 2024 (five years from the effective date of the AD Pharma Agreement), however effective with the October 2020 amendment to the AD Pharma Agreement, this option and right was rescinded. In March 2017, we granted MainPointe an exclusive license to our IMPEDE ® Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada. On January 1, 2020, MainPointe assigned to AD Pharma, with Acura’s consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura; which was rescinded by AD Pharma in October 2020.

COMMON STOCK PURCHASE WARRANTS

COMMON STOCK PURCHASE WARRANTS	9 Months Ended
	Sep. 30, 2021
COMMON STOCK PURCHASE WARRANTS.
COMMON STOCK PURCHASE WARRANTS	NOTE 9 – COMMON STOCK PURCHASE WARRANTS Our warrant activity during the nine month periods ended September 30, 2021 and 2020 is shown below (in thousands except price data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2021 ​ 2020 ​ ​ WAvg ​ WAvg ​ ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ Number ​ Price ​ Number ​ Price Outstanding, Jan. 1 11,782 ​ $ 0.09 11,842 ​ $ 0.10 Issued — ​ — — ​ — Exercised — ​ — — ​ — Expired — ​ — — ​ — Modification — ​ — — ​ — Outstanding, Sept. 30 11,782 ​ $ 0.09 11,842 ​ $ 0.10 ​ As part of our July 2017 private placement transaction with Mr. Schutte, we issued warrants to purchase 1,782,531 shares of our common stock. The warrants are immediately exercisable at a price of $0.528 per share and expire five years after issuance in July 2022. (See Note 8). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted for these warrants as equity. In June 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance in June 2024. We obtained a valuation of fair value on the warrant and $1.145 million was allocated to the warrant and accounted for as equity. (See Note 7 and Note 8). The warrant for 10.0 million shares was assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019. During December 2020, warrants expired that were exercisable for 60 thousand shares of our common stock and had an exercise price of $2.52 per share.

STOCK-BASED COMPENSATION EXPENS

STOCK-BASED COMPENSATION EXPENSE	9 Months Ended
	Sep. 30, 2021
STOCK-BASED COMPENSATION EXPENSE
STOCK-BASED COMPENSATION EXPENSE	NOTE 10 – STOCK-BASED COMPENSATION EXPENSE We have several stock-based compensation plans covering stock options and RSUs for our employees and directors. We measure our compensation cost related to stock-based payment transactions based on fair value of the equity or liability classified instrument. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for stock-based compensation for RSUs is based on the closing market price of our common stock on the date of grant. Our total stock-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 ​ (in thousands) Research and development costs: ​ ​ ​ ​ Stock options ​ $ — ​ $ — ​ $ — ​ $ — Restricted stock units ​ — ​ — ​ — ​ — Subtotal ​ $ — ​ $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ General and administrative costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock options ​ $ — ​ $ — ​ $ — ​ $ — Restricted stock units ​ 21 ​ 9 ​ 84 ​ 42 Subtotal ​ ​ 21 ​ ​ 9 ​ ​ 84 ​ ​ 42 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ $ 21 ​ $ 9 ​ $ 84 ​ $ 42 ​ Stock Option Plans We maintain various stock option plans. A summary of our stock option plans as of September 30, 2021 and 2020 and for the nine months then ended consisted of the following (in thousands except exercise price): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months Ended September 30, ​ ​ 2021 ​ 2020 ​ ​ Weighted ​ Weighted ​ ​ Number ​ Average ​ ​ ​ Average ​ ​ of ​ Exercise ​ Number of ​ Exercise ​ ​ Options ​ Price ​ Options ​ Price Outstanding, Jan. 1 1,254 ​ $ 3.46 1,356 ​ $ 4.45 Granted — ​ — — ​ — Exercised (80) ​ 0.15 — ​ — Forfeited — ​ — — ​ — Expired ​ (12) ​ ​ 17.30 ​ (12) ​ ​ 27.35 Outstanding, Sept. 30 1,162 ​ $ 3.55 1,344 ​ $ 4.24 Exercisable, Sept. 30 1,162 ​ $ 3.55 1,344 ​ $ 4.24 ​ We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity. Historically, the majority of our stock options have been held until their expiration date. The intrinsic value contained in the stock option awards which are vested and outstanding at September 30, 2021 is approximately $67 thousand. Restricted Stock Unit Award Plans We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2021 Restricted Stock Unit Award Plan (the “2021 RSU Plan) and a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. Our non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The portion of the RSU awards subject to cash settlement are recorded as a liability in the Company’s consolidated balance sheet as they vest and being marked-to-market each reporting period until they are distributed. The liability was $41 thousand at September 30, 2021. The compensation cost to be incurred on a granted RSU without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense and recorded to additional paid-in capital over the vesting period of the RSU award. A summary of the grants under the RSU Plans as of September 30, 2021 and 2020, and for the nine months then ended consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months Ended September 30, ​ ​ 2021 ​ 2020 ​ ​ Number of ​ Number of ​ ​ Number ​ Vested ​ Number of ​ Vested ​ ​ of RSUs ​ RSUs ​ RSUs ​ RSUs Outstanding, Jan. 1 839 839 ​ 1,017 1,017 Granted 267 — ​ 219 — Distributed (447) (447) ​ (397) (397) Vested — 200 ​ — 165 Forfeited — — ​ — — Outstanding, Sept. 30 659 592 ​ 839 785 ​ 2021 Restricted Stock Unit Award Plan Our 2021 RSU Plan was approved by shareholders in May 2021 and permits the grant of up to 2.50 million shares of our common stock pursuant to awards under the 2021 RSU Plan. As of September 30, 2021, there are 2.23 million shares which remain available for award under the 2021 RSU Plan. Information about the award activity under the 2021 RSU Plan is as follows: ● In May 2021, we awarded approximately 66 thousand RSUs to each of our four non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. The awards vest 50% at the end of calendar quarter June 30, 2021 and 25% at the end of each calendar quarter in 2021 thereafter. Settlement of this RSU will occur on January 4, 2022 the first business day of the year after vesting. The portion of the RSU awards which is subject to cash settlement will also be subject to marked-to market accounting having a liability recorded on the Company’s consolidated balance sheet with quarterly adjustments recorded to stock compensation expense in the general and administration operating category of our income statement. 2017 Restricted Stock Unit Award Plan Our 2017 RSU Plan was approved by shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. There are no shares which remain available for award under the 2017 RSU Plan. Information about the award activity under the 2017 RSU Plan is as follows: ● In December 2017, we awarded 200 thousand RSUs to our employees. Such RSU awards vested 100% after one full year of service. Distributions of the vested RSU awards to the employees are being made in three equal installments on the first business day of each of January 2020, 2021, and 2022 or earlier upon a qualifying change of control. ● In December 2018, we awarded 488 thousand RSUs to our employees. Such RSU awards vested 100% after one full year of service. Distributions of the vested RSU awards to the employees are being made in three equal installments on the first business day of each of January 2021, 2022, and 2023 or earlier upon a qualifying change of control. ● In January 2019, we awarded approximately 83 thousand RSUs to each of our four non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. The awards vested 25% at the end of each calendar quarter in 2019. Settlement of this RSU award occurred on January 2, 2020, the first business day of the year after vesting. The portion of the RSU awards which were subject to cash settlement was also subject to marked-to market accounting having a liability recorded on the Company’s consolidated balance sheet with quarterly adjustments which were recorded to stock compensation expense in the general and administration operating category of our income statement. ● In January 2020, we awarded approximately 55 thousand RSUs to each of our four non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. The awards vested 25% at the end of each calendar quarter in 2020. Settlement of this RSU award did occur on January 4, 2021, the first business day of the year after vesting. The portion of the RSU awards which are subject to cash settlement will also be subject to marked-to market accounting having a liability recorded on the Company’s consolidated balance sheet with quarterly adjustments recorded to stock compensation expense in the general and administration operating category of our income statement. Information about the distribution of share activity under the 2017 RSU Plan is as follows: ● In January 2019, 267 thousand RSUs were distributed to our non-employee directors from their January 2018 award and settled in common stock. ● In January 2020, 333 thousand RSUs were distributed to our non-employee directors from their January 2019 award with 296 thousand RSUs settled in common stock, 4 thousand RSUs used to settle the purchase price and 33 thousand RSUs settled in cash. ● In January 2020, 64 thousand RSUs were distributed to our current and former employees representing one third of their 2017 award with 54 thousand RSUs settled in common stock and 10 thousand RSUs used to settle the purchase price and employee withholding taxes. ● In January 2021, 219 thousand RSUs were distributed to our non-employee directors from their January 2020 award and settled in common stock. ● In January 2021, 228 thousand RSUs were distributed to our current and former employees representing one third of their December 2017 award and one third of their December 2018 award, with 185 thousand RSUs settled in common stock and 43 thousand RSUs used to settle the purchase price and employee withholding taxes.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2021
LEASES
LEASES	NOTE 11 – LEASES In June 2021, the Company entered into a finance lease for a scientific piece of equipment for a term of 24 months with equal monthly payment of $3 thousand. The following table reflects supplemental balance sheet information related to the lease as of September 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ Financial Statement Classification 2021 2020 ​ ​ ​ ​ (in thousands) Assets ​ ​ Finance lease right of use Other long-term assets ​ $ 59 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ Finance lease liability - current Other current liabilities ​ $ 33 ​ $ — Finance lease liability - noncurrent Other long-term liabilities ​ 25 ​ — Total lease liability ​ ​ ​ 58 ​ $ — ​

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
INCOME TAXES
INCOME TAXES	NOTE 12 – INCOME TAXES We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $138 million gross Federal NOLs at September 30, 2021. On June 9, 2021 we believe the conversion for the $6.0 million Promissory Note and approximately $877 thousand of accrued but unpaid interest into 42,984,375 shares of the Company’s common stock created another qualifying event under IRC 382 which will most likely continue to further limit our utilization of our NOLs. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 available to offset taxable income and prior to the June 9, 2021 conversion, was less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 while our Federal NOLs generated after 2017 can be carried forward indefinitely. Future common stock transactions, such as the exercise of common stock purchase warrants, may cause additional qualifying events under IRC 382 which will most likely continue to further limit our utilization of our NOLs. The realization of deferred income tax assets is dependent upon future earnings, if any, and the timing and amount of which may be uncertain. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At September 30, 2021 and December 31, 2020, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2021
NET INCOME (LOSS) PER SHARE
NET INCOME (LOSS) PER SHARE	NOTE 13 –NET INCOME (LOSS) PER SHARE Basic net income (loss) per share is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to both vested Restricted Stock Units (“RSUs”) which settle in shares (See Note 10) and a stock warrant exercisable for 10.0 million shares having an exercise price of $0.01 per share (See Note 7). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. As the Company reported a net loss for the nine month periods ending September 30, 2021 and 2020, the effects of common stock equivalents were excluded as the diluted net loss per share calculation would have been antidilutive. The weighted-average common share outstanding diluted computation is not impacted during the reported period when the exercise price of a stock option, common stock warrant or convertible loan is greater than the average market price of our common stock the reported period. A reconciliation of the numerators and denominators of basic and diluted net income (loss) per share (“EPS”) consisted of the following (in thousands except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Basic net loss per share ​ ​ ​ ​ Numerator: net loss ​ $ (262) ​ $ (678) ​ $ (908) ​ $ (965) Denominator (weighted average): ​ ​ ​ ​ ​ ​ ​ ​ Common shares ​ 65,089 ​ 21,650 ​ 40,044 ​ 21,650 RSUs – vested ​ 472 ​ 686 ​ 419 ​ 654 Common stock purchase warrants ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 Basic weighted average shares outstanding ​ 75,561 ​ 32,336 ​ 50,464 ​ 32,304 Basic net loss per share ​ $ (0.00) ​ $ (0.02) ​ $ (0.02) ​ $ (0.03) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net loss per share ​ ​ ​ ​ ​ Numerator: net loss ​ $ (262) ​ $ (678) ​ $ (908) ​ $ (965) Denominator (weighted average): ​ ​ ​ ​ ​ ​ ​ ​ Common shares ​ 65,089 ​ 21,650 ​ 40,044 ​ 21,650 RSUs ​ 472 ​ 686 ​ 419 ​ 654 Common stock purchase warrants ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 Diluted weighted average shares outstanding ​ 75,561 ​ 32,336 ​ 50,464 ​ 32,304 Diluted net loss per share ​ $ (0.00) ​ $ (0.02) ​ $ (0.02) ​ $ (0.03) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Excluded securities (non-weighted): ​ ​ ​ ​ ​ ​ ​ ​ Common shares issuable: ​ ​ ​ ​ ​ ​ ​ ​ RSUs ​ 147 ​ 121 ​ 147 ​ 121 Stock options ​ 1,162 ​ 1,344 ​ 1,162 ​ 1,344 Common stock purchase warrants ​ 1,782 ​ 1,842 ​ 1,782 ​ 1,842 Convertible loan ​ ​ — ​ ​ 37,500 ​ ​ — ​ ​ 37,500 Total excluded potentially dilutive shares ​ 3,091 ​ 40,807 ​ 3,091 ​ 40,807 ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 14 – SUBSEQUENT EVENTS In October and November 2021, AD Pharma remitted to us $350 thousand of the $400 thousand license fees. In October 2021, the Company received approval for loan forgiveness under the PPP by the Small Business Administration for its 2 nd

LICENSE AND COLLABORATION AGR_2

LICENSE AND COLLABORATION AGREEMENTS (Tables)	9 Months Ended
	Sep. 30, 2021
LICENSE AND COLLABORATION AGREEMENTS
Summary of Aversion intangible asset	The Aversion intangible asset is summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, December 31, ​ ​ 2021 ​ 2020 Intangible asset – Aversion ​ 2,000 ​ 2,000 Less: accumulated amortization ​ (1,279) ​ (1,259) Less: reserve for impairment ​ (668) ​ (668) Net ​ $ 53 ​ $ 73

REVENUE FROM CONTRACTS WITH C_2

REVENUE FROM CONTRACTS WITH CUSTOMERS (Tables)	9 Months Ended
	Sep. 30, 2021
REVENUE FROM CONTRACTS WITH CUSTOMERS
Schedule of disaggregation of revenue	Royalty revenues by licensee are summarized below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Assertio (Oxaydo) ​ $ 67 ​ $ 11 ​ $ 100 ​ $ 72 MainPointe - related party (Nexafed) ​ — ​ 3 ​ ​ 2 ​ ​ 9 Royalty revenues ​ $ 67 ​ $ 14 ​ $ 102 ​ $ 81

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2021
PROPERTY, PLANT AND EQUIPMENT
Schedule of Property, Plant and equipment	Property, plant and equipment is summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2021 2020 ​ ​ (in thousands) Building and improvements ​ $ 1,273 ​ $ 1,273 Scientific equipment ​ 597 ​ 597 Computer hardware and software ​ 104 ​ 106 Machinery and equipment ​ 274 ​ 274 Land and improvements ​ 162 ​ 162 Other personal property ​ 69 ​ 70 Office equipment ​ 27 ​ 27 Total ​ 2,506 ​ 2,509 Less: accumulated depreciation ​ (2,057) ​ (2,025) Net property, plant and equipment ​ $ 449 ​ $ 484

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2021
ACCRUED EXPENSES
Schedule of Accrued expenses	Accrued expenses are summarized as follows (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ 2021 2020 ​ ​ (in thousands) Cost sharing expenses under license agreements ​ $ 428 ​ $ 428 Other fees and services ​ 26 ​ 24 Payroll, payroll taxes and benefits ​ 39 ​ 8 Professional services ​ 157 ​ 117 Financed premiums on insurance policies ​ 83 ​ 28 Property taxes ​ 7 ​ 9 Franchise taxes ​ 31 ​ 17 Total ​ $ 771 ​ $ 631

COMMON STOCK PURCHASE WARRANTS

COMMON STOCK PURCHASE WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2021
COMMON STOCK PURCHASE WARRANTS.
Schedule Of Common Stock Warrant Activity	Our warrant activity during the nine month periods ended September 30, 2021 and 2020 is shown below (in thousands except price data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2021 ​ 2020 ​ ​ WAvg ​ WAvg ​ ​ ​ ​ Exercise ​ ​ ​ Exercise ​ ​ Number ​ Price ​ Number ​ Price Outstanding, Jan. 1 11,782 ​ $ 0.09 11,842 ​ $ 0.10 Issued — ​ — — ​ — Exercised — ​ — — ​ — Expired — ​ — — ​ — Modification — ​ — — ​ — Outstanding, Sept. 30 11,782 ​ $ 0.09 11,842 ​ $ 0.10

SHARE-BASED COMPENSATION EXPENS

SHARE-BASED COMPENSATION EXPENSE (Tables)	9 Months Ended
	Sep. 30, 2021
STOCK-BASED COMPENSATION EXPENSE
Schedule of employee service share-based compensation, allocation of recognized period costs	Our total stock-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 ​ (in thousands) Research and development costs: ​ ​ ​ ​ Stock options ​ $ — ​ $ — ​ $ — ​ $ — Restricted stock units ​ — ​ — ​ — ​ — Subtotal ​ $ — ​ $ — ​ $ — ​ $ — ​ ​ ​ ​ ​ General and administrative costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock options ​ $ — ​ $ — ​ $ — ​ $ — Restricted stock units ​ 21 ​ 9 ​ 84 ​ 42 Subtotal ​ ​ 21 ​ ​ 9 ​ ​ 84 ​ ​ 42 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ $ 21 ​ $ 9 ​ $ 84 ​ $ 42
Schedule of share-based compensation, stock option plan activity	A summary of our stock option plans as of September 30, 2021 and 2020 and for the nine months then ended consisted of the following (in thousands except exercise price): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months Ended September 30, ​ ​ 2021 ​ 2020 ​ ​ Weighted ​ Weighted ​ ​ Number ​ Average ​ ​ ​ Average ​ ​ of ​ Exercise ​ Number of ​ Exercise ​ ​ Options ​ Price ​ Options ​ Price Outstanding, Jan. 1 1,254 ​ $ 3.46 1,356 ​ $ 4.45 Granted — ​ — — ​ — Exercised (80) ​ 0.15 — ​ — Forfeited — ​ — — ​ — Expired ​ (12) ​ ​ 17.30 ​ (12) ​ ​ 27.35 Outstanding, Sept. 30 1,162 ​ $ 3.55 1,344 ​ $ 4.24 Exercisable, Sept. 30 1,162 ​ $ 3.55 1,344 ​ $ 4.24
Schedule of grants under the RSU Plans	A summary of the grants under the RSU Plans as of September 30, 2021 and 2020, and for the nine months then ended consisted of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine months Ended September 30, ​ ​ 2021 ​ 2020 ​ ​ Number of ​ Number of ​ ​ Number ​ Vested ​ Number of ​ Vested ​ ​ of RSUs ​ RSUs ​ RSUs ​ RSUs Outstanding, Jan. 1 839 839 ​ 1,017 1,017 Granted 267 — ​ 219 — Distributed (447) (447) ​ (397) (397) Vested — 200 ​ — 165 Forfeited — — ​ — — Outstanding, Sept. 30 659 592 ​ 839 785

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2021
LEASES
Schedule of supplemental balance sheet information related to the lease	The following table reflects supplemental balance sheet information related to the lease as of September 30, 2021 and December 31, 2020 (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ Financial Statement Classification 2021 2020 ​ ​ ​ ​ (in thousands) Assets ​ ​ Finance lease right of use Other long-term assets ​ $ 59 ​ $ — ​ ​ ​ ​ ​ ​ ​ ​ ​ Liabilities ​ ​ Finance lease liability - current Other current liabilities ​ $ 33 ​ $ — Finance lease liability - noncurrent Other long-term liabilities ​ 25 ​ — Total lease liability ​ ​ ​ 58 ​ $ —

NET INCOME (LOSS) PER SHARE (Ta

NET INCOME (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
NET INCOME (LOSS) PER SHARE
Schedule of reconciliation of basic and diluted	A reconciliation of the numerators and denominators of basic and diluted net income (loss) per share (“EPS”) consisted of the following (in thousands except per share data): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months Ended ​ Nine months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Basic net loss per share ​ ​ ​ ​ Numerator: net loss ​ $ (262) ​ $ (678) ​ $ (908) ​ $ (965) Denominator (weighted average): ​ ​ ​ ​ ​ ​ ​ ​ Common shares ​ 65,089 ​ 21,650 ​ 40,044 ​ 21,650 RSUs – vested ​ 472 ​ 686 ​ 419 ​ 654 Common stock purchase warrants ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 Basic weighted average shares outstanding ​ 75,561 ​ 32,336 ​ 50,464 ​ 32,304 Basic net loss per share ​ $ (0.00) ​ $ (0.02) ​ $ (0.02) ​ $ (0.03) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net loss per share ​ ​ ​ ​ ​ Numerator: net loss ​ $ (262) ​ $ (678) ​ $ (908) ​ $ (965) Denominator (weighted average): ​ ​ ​ ​ ​ ​ ​ ​ Common shares ​ 65,089 ​ 21,650 ​ 40,044 ​ 21,650 RSUs ​ 472 ​ 686 ​ 419 ​ 654 Common stock purchase warrants ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 ​ ​ 10,000 Diluted weighted average shares outstanding ​ 75,561 ​ 32,336 ​ 50,464 ​ 32,304 Diluted net loss per share ​ $ (0.00) ​ $ (0.02) ​ $ (0.02) ​ $ (0.03) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Excluded securities (non-weighted): ​ ​ ​ ​ ​ ​ ​ ​ Common shares issuable: ​ ​ ​ ​ ​ ​ ​ ​ RSUs ​ 147 ​ 121 ​ 147 ​ 121 Stock options ​ 1,162 ​ 1,344 ​ 1,162 ​ 1,344 Common stock purchase warrants ​ 1,782 ​ 1,842 ​ 1,782 ​ 1,842 Convertible loan ​ ​ — ​ ​ 37,500 ​ ​ — ​ ​ 37,500 Total excluded potentially dilutive shares ​ 3,091 ​ 40,807 ​ 3,091 ​ 40,807

OPERATIONS AND SUMMARY OF SIG_2

OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Jun. 28, 2019	Oct. 09, 2015	Nov. 30, 2021	Oct. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2021	Apr. 29, 2020	Dec. 31, 2020	Jul. 31, 2021	Sep. 30, 2020	Dec. 31, 2019
Cash							$ 89	$ 89		$ 413		$ 493	$ 862
Working Capital Deficit							135	135
Accumulated deficit							390,112	390,112		389,204
Income (loss) from operation								977		758
Net loss								908		$ 1,200
Monthly license payment receivable		$ 5,000
AD Pharma Amended Agreement
License fees								$ 350
Monthly license payment receivable	$ 350								$ 350		$ 200
AD Pharma Amended Agreement | Abuse Deterrent Pharma, LLC
License fees						$ 400
Reimbursable development expense					$ 72
Monthly license payment receivable							$ 200				$ 200
Subsequent event | AD Pharma Amended Agreement
Monthly license payment receivable			$ 400	$ 350
Subsequent event | AD Pharma Amended Agreement | Abuse Deterrent Pharma, LLC
License fees			$ 400
Monthly license payment receivable				$ 350

LICENSE AND COLLABORATION AGR_3

LICENSE AND COLLABORATION AGREEMENTS (Details) - USD ($) $ in Thousands

Jun. 28, 2019

Mar. 31, 2017

Oct. 09, 2015

Nov. 30, 2021

Oct. 31, 2021

Jul. 31, 2021

Jun. 30, 2021

Mar. 31, 2017

Oct. 31, 2016

Apr. 30, 2014

Sep. 30, 2021

Mar. 31, 2020

Sep. 30, 2021

Sep. 30, 2020

Apr. 29, 2020

Jul. 31, 2021

License Development and Commercialization Agreement [Line Items]

Payment for Termination

$ 2,000

Proceeds from Milestone Payment On Agreement

$ 2,500

Monthly license payment receivable

$ 5,000

Finite-Lived Intangible Asset, Useful Life

9 years 8 months 12 days

2 years

Amortization of intangible asset

$ 20

$ 64

Impairment charge against the intangible asset

$ 668

0

$ 668

Expected amortization expense for patents per quarter.

$ 6

6

Patents

License Development and Commercialization Agreement [Line Items]

Payment for Termination

$ 2,000

AD Pharma Amended Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 350

$ 350

$ 200

License fees

$ 350

Abuse Deterrent Pharma, LLC | AD Pharma Amended Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 200

$ 200

Reimbursable development expense

$ 72

License fees

$ 400

MainPointe Pharmaceuticals, LLC | AD Pharma Amended Agreement

License Development and Commercialization Agreement [Line Items]

Waiver of exercise price if exercise of option occurs by certain date

$ 500

Period from effective date for exercise of option

5 years

Subsequent event | AD Pharma Amended Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 400

$ 350

Subsequent event | Abuse Deterrent Pharma, LLC | AD Pharma Amended Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 350

License fees

$ 400

MainPointe

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 2,500

Licensing Agreement, Royalty Percentage

7.50%

License Agreement Option Products Description

In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede Technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.

MainPointe | UNITED KINGDOM

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 1,000

MainPointe | JAPAN

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 500

MainPointe | South Korea

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 250

Kempharm Agreement

License Development and Commercialization Agreement [Line Items]

Monthly license payment receivable

$ 3,500

Kempharm Agreement | Minimum

License Development and Commercialization Agreement [Line Items]

Additional Upfront Payment Receivable

$ 1,000

LICENSE AND COLLABORATION AGR_4

LICENSE AND COLLABORATION AGREEMENTS - Intangible asset (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
LICENSE AND COLLABORATION AGREEMENTS
Intangible asset - Aversion	$ 2,000	$ 2,000
Less: accumulated amortization	(1,279)	(1,259)
Less: reserve for impairment	(668)	(668)
Net	$ 53	$ 73

REVENUE FROM CONTRACTS WITH C_3

REVENUE FROM CONTRACTS WITH CUSTOMERS - Additional Information (Details) - USD ($) $ in Thousands	Jun. 28, 2019	Oct. 09, 2015	Nov. 30, 2021	Oct. 31, 2021	Jul. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Apr. 29, 2020	Jul. 31, 2021
Contract Balance And Performance Obligations description										The Company had no contract assets and contract liability balances under the license and collaboration agreements at either September 30, 2021 or 2020.
Monthly license payment receivable		$ 5,000
Product sales return allowance liability							$ 0		$ 223	$ 0	$ 223
Sales return allowance liability								$ 0			0
License fees received							200	$ 300		1,400	$ 2,400
AD Pharma Amended Agreement
Monthly license payment receivable	$ 350											$ 350	$ 200
License fees										$ 350
AD Pharma Amended Agreement | Subsequent event
Monthly license payment receivable			$ 400	$ 350
Abuse Deterrent Pharma, LLC | AD Pharma Amended Agreement
Monthly license payment receivable							$ 200						$ 200
License fees						$ 400
Reimbursable development expense					$ 72
Abuse Deterrent Pharma, LLC | AD Pharma Amended Agreement | Subsequent event
Monthly license payment receivable				$ 350
License fees			$ 400

REVENUE FROM CONTRACTS WITH C_4

REVENUE FROM CONTRACTS WITH CUSTOMERS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Royalty revenues	$ 67	$ 14	$ 102	$ 81
Assertio (Oxaydo)
Royalty revenues	67	11	100	72
MainPointe
Royalty revenues	$ 0	$ 3	$ 2	$ 9

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total	$ 2,506	$ 2,509
Less: accumulated depreciation	(2,057)	(2,025)
Net property, plant and equipment	449	484
Building and improvements
Property, Plant and Equipment [Line Items]
Total	1,273	1,273
Scientific equipment
Property, Plant and Equipment [Line Items]
Total	597	597
Computer hardware and software
Property, Plant and Equipment [Line Items]
Total	104	106
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	274	274
Land and improvements
Property, Plant and Equipment [Line Items]
Total	162	162
Other personal property
Property, Plant and Equipment [Line Items]
Total	69	70
Office equipment
Property, Plant and Equipment [Line Items]
Total	$ 27	$ 27

PROPERTY, PLANT AND EQUIPMENT -

PROPERTY, PLANT AND EQUIPMENT - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
PROPERTY, PLANT AND EQUIPMENT
Depreciation	$ 12	$ 13	$ 35	$ 42

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
ACCRUED EXPENSES
Cost sharing expenses under license agreements	$ 428	$ 428
Other fees and services	26	24
Payroll, payroll taxes and benefits	39	8
Professional services	157	117
Financed premiums on insurance policies	83	28
Property taxes	7	9
Franchise taxes	31	17
Total	$ 771	$ 631

DEBT - Additional Information (

DEBT - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands

Jun. 09, 2021

Mar. 16, 2021

Jun. 28, 2019

Jun. 27, 2019

Dec. 31, 2018

Sep. 30, 2020

Jun. 27, 2019

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2018

Dec. 31, 2020

Apr. 13, 2020

Jun. 30, 2019

Debt Instrument [Line Items]

Common shares exercise price

$ 2.52

$ 0.01

Schutte

Debt Instrument [Line Items]

Amount borrowed from related party

$ 650

$ 4,350

Debt instrument principal amount

$ 5,000

Proceeds from Issuance of Long-term Debt

725

$ 650

$ 4,350

Aggregate principal of promissory notes and accrued interest

$ 6,000

Debt instrument, interest rate, stated percentage

7.50%

Common shares exercise price

$ 0.01

Principal and interest converted shares

37,500,000

Issued warrant

10,000,000

Share Price

$ 0.16

Schutte Note

Debt Instrument [Line Items]

Proceeds from Issuance of Long-term Debt

$ 725

Aggregate principal of promissory notes and accrued interest

$ 6,000

Debt instrument, interest rate, stated percentage

7.50%

Common stock warrant exercisable outstanding, shares

6,000,000

Common shares exercise price

$ 0.01

$ 0.01

Principal and interest converted shares

37,500,000

Issued warrant

10,000,000

10,000,000

Share Price

$ 0.16

Interest expense

$ 113

$ 200

$ 338

1st PPP Loan

Debt Instrument [Line Items]

Debt instrument principal amount

$ 269

2nd PPP Loan

Debt Instrument [Line Items]

Debt instrument principal amount

$ 266

Loan term

5 years

AD Pharma Amended Agreement | Abuse Deterrent Pharma, LLC

Debt Instrument [Line Items]

Principal and interest converted shares

42,984,375

Conversion received

$ 6,000

Unpaid interest

$ 877

Acura Pharmaceuticals Inc

Debt Instrument [Line Items]

Ownership percentage

66.00%

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($)

Jun. 09, 2021

Jun. 28, 2019

Jun. 27, 2019

Dec. 31, 2018

Oct. 09, 2015

Nov. 30, 2021

Oct. 31, 2021

Jul. 31, 2021

Jun. 30, 2021

Jul. 31, 2017

Mar. 31, 2017

Sep. 30, 2021

Sep. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Apr. 29, 2020

Jul. 31, 2021

Dec. 31, 2020

Jun. 30, 2019

Related Party Transaction [Line Items]

Number of common stock need to hold to designate as director.

600,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 2.52

$ 0.01

Warrant to purchase shares of common stock

60,000

10,000,000

Class Of Warrants Or Rights, Expiry Period

5 years

Proceeds from License Fees Received

$ 5,000,000

Acura Pharmaceuticals Inc

Related Party Transaction [Line Items]

Noncontrolling Interest, Ownership Percentage by Parent

66.00%

AD Pharma Amended Agreement

Related Party Transaction [Line Items]

Proceeds from License Fees Received

$ 350,000

$ 350,000

$ 200,000

License fees

$ 350,000

Subsequent event | AD Pharma Amended Agreement

Related Party Transaction [Line Items]

Proceeds from License Fees Received

$ 400,000

$ 350,000

Subsequent event | AD Pharma Amended Agreement | Acura Pharmaceuticals Inc

Related Party Transaction [Line Items]

License fees

400,000

MainPointe

Related Party Transaction [Line Items]

Licensing Agreement, Royalty Percentage

7.50%

Proceeds from License Fees Received

$ 2,500,000

MainPointe | Royalty

Related Party Transaction [Line Items]

Royalty revenues

$ 0

$ 3,000

2,000

$ 9,000

Investor

Related Party Transaction [Line Items]

Warrant to purchase shares of common stock

1,782,531

Investor | Private Placement

Related Party Transaction [Line Items]

Sale of Stock, Consideration Received on Transaction

$ 4,000,000

Sale of Stock, Number of Shares Issued in Transaction

8,912,655

Sale of Stock, Price Per Share

$ 0.4488

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.528

Sale Of Stock, Issue Price Description

85%

Warrants Not Settleable in Cash, Fair Value Disclosure

495,000

495,000

Proceeds from Issuance of Warrants

$ 4,000,000

Warrant to purchase shares of common stock

1,782,532

Schutte

Related Party Transaction [Line Items]

Aggregate principal of promissory notes and accrued interest

$ 6,000,000

Fixed interest rate

7.50%

Share Price

$ 0.16

Debt Conversion, Converted Instrument, Warrants or Options Issued

10,000,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 0.01

Debt Conversion, Converted Instrument, Shares Issued

37,500,000

Proceeds from Issuance of Long-term Debt

$ 725,000

$ 650,000

$ 4,350,000

Abuse Deterrent Pharma, LLC | AD Pharma Amended Agreement

Related Party Transaction [Line Items]

Debt Conversion, Converted Instrument, Shares Issued

42,984,375

Proceeds from License Fees Received

$ 200,000

$ 200,000

License fees

$ 400,000

Reimbursable development expense

$ 72,000

Debt Conversion, Original Debt, Amount

$ 6,000,000

Unpaid interest

$ 877,000

Abuse Deterrent Pharma, LLC | Subsequent event | AD Pharma Amended Agreement

Related Party Transaction [Line Items]

Proceeds from Issuance of Warrants

350,000

Proceeds from License Fees Received

$ 350,000

License fees

$ 400,000

Abuse Deterrent Pharma, LLC | MainPointe

Related Party Transaction [Line Items]

Option product exercise price waived if the exercise of the option occurred by five years

$ 500,000

Period to waive option product exercise price

5 years

COMMON STOCK PURCHASE WARRANT_2

COMMON STOCK PURCHASE WARRANTS - Warrant Activity (Details) - Common stock purchase warrants - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Number of Options
Number of Options Outstanding, beginning	11,782	11,842
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	0
Number of Options, Modification	0	0
Number of Options Outstanding, ending	11,782	11,842
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 0.09	$ 0.10
Weighted Average Exercise Price, Issued	0	0
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Expired	0	0
Weighted Average Exercise Price, Modification	0	0
Weighted Average Exercise Price, ending	$ 0.09	$ 0.10

COMMON STOCK PURCHASE WARRANT_3

COMMON STOCK PURCHASE WARRANTS - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Jun. 30, 2019	Jul. 31, 2017	Sep. 30, 2021	Dec. 31, 2020	Jun. 28, 2019
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock	10,000,000			60,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01			$ 2.52
Warrants expiration term	5 years
Class Of Warrant Or Right Term		5 years
Stock Issued During Period, Value, New Issues		$ 4,000
Schutte Note
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.01		$ 0.01
Private Placement
Class of Warrant or Right [Line Items]
Stock Issued During Period, Value, New Issues		$ 495
Investor
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock		1,782,531
Investor | Private Placement
Class of Warrant or Right [Line Items]
Warrant to purchase shares of common stock		1,782,532
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.528
Schutte
Class of Warrant or Right [Line Items]
Shares of warrant assigned and transferred					10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.01
Amount allocated to warrant	$ 1,145

STOCK-BASED COMPENSATION EXPE_2

STOCK-BASED COMPENSATION EXPENSE - Non-Cash Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total Stock Compensation
Allocated Share-based Compensation Expense	$ 21	$ 9	$ 84	$ 42
Research and development expense:
Total Stock Compensation
Allocated Share-based Compensation Expense	0	0	0	0
Research and development expense: | Stock option awards
Total Stock Compensation
Allocated Share-based Compensation Expense	0	0	0	0
Research and development expense: | Restricted Stock Units (RSUs)
Total Stock Compensation
Allocated Share-based Compensation Expense	0	0	0	0
General and administrative expense:
Total Stock Compensation
Allocated Share-based Compensation Expense	21	9	84	42
General and administrative expense: | Stock option awards
Total Stock Compensation
Allocated Share-based Compensation Expense	0	0	0	0
General and administrative expense: | Restricted Stock Units (RSUs)
Total Stock Compensation
Allocated Share-based Compensation Expense	$ 21	$ 9	$ 84	$ 42

STOCK-BASED COMPENSATION EXPE_3

STOCK-BASED COMPENSATION EXPENSE - Stock Option plan activity (Details) - Stock Option Plan - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,254	1,356
Number of Options, Granted	0	0
Number of Options, Exercised	(80)	0
Number of Options, Forfeited	0	0
Number of Options, Expired	(12)	(12)
Number of Options Outstanding, ending	1,162	1,344
Number of Options exercisable	1,162	1,344
Weighted Average Exercise Price, beginning	$ 3.46	$ 4.45
Weighted Average Exercise Price, Granted	0	0
Weighted Average Exercise Price, Exercised	0.15	0
Weighted Average Exercise Price, Forfeited	0	0
Weighted Average Exercise Price, Expired	17.30	27.35
Weighted Average Exercise Price, ending	3.55	4.24
Weighted Average Exercise Price, Options exercisable	$ 3.55	$ 4.24

STOCK-BASED COMPENSATION EXPE_4

STOCK-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Restricted Stock Units
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	839	1,017
Granted	267	219
Distributed	(447)	(397)
Vested	0	0
Forfeited	0	0
Outstanding, ending	659	839
Vested Restricted Stock Units (RSUs)
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	839	1,017
Granted	0	0
Distributed	(447)	(397)
Vested	200	165
Forfeited	0	0
Outstanding, ending	592	785

STOCK-BASED COMPENSATION EXPE_5

STOCK-BASED COMPENSATION EXPENSE - Additional Information (Details) - USD ($) $ in Thousands	1 Months Ended						9 Months Ended
	May 31, 2021	Jan. 31, 2021	Jan. 31, 2020	Jan. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2021	Nov. 30, 2017
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested							$ 67
Restricted Stock Units (RSUs) | Director
Employee Benefit Plans Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability							$ 41
Restricted Stock Units (RSUs) | Restricted Stock Unit Award Plan, 2021 [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							2,230,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,500,000
Restricted Stock Units (RSUs) | Restricted Stock Unit Award Plan, 2021 [Member] | Four Non Employee Directors
Employee Benefit Plans Disclosure [Line Items]
Share Based Compensation, Non Employee Services Transaction, Cash Settlement, Percentage	40.00%
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period	66,000
Restricted Stock Units (RSUs) | Restricted Stock Unit Award Plan, 2021 [Member] | Four Non Employee Directors | Vesting at the end of calendar quarter June 30, 2021
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	50.00%
Restricted Stock Units (RSUs) | Restricted Stock Unit Award Plan, 2021 [Member] | Four Non Employee Directors | Vesting at each end of calendar quarter in 2021 thereafter.
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
2017 Restricted Stock Unit Award Plan
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant							0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage					100.00%	100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description							stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								1,500,000
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period					488,000	200,000
2017 Restricted Stock Unit Award Plan | Employees
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		228,000	64,000
2017 Restricted Stock Unit Award Plan | Employees | Distributed And Settled In Common Stock
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		185,000	54,000
2017 Restricted Stock Unit Award Plan | Employees | Settlement For Purchase Price
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		43,000	10,000
2017 Restricted Stock Unit Award Plan | Four Non Employee Directors
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description			stock, for up to 40%	stock, for up to 40%
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period			55,000	83,000
Non-employee director | 2017 Restricted Stock Unit Award Plan
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period			333,000
Non-employee director | 2017 Restricted Stock Unit Award Plan | Settled In Cash
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period			33,000
Non-employee director | 2017 Restricted Stock Unit Award Plan | Distributed And Settled In Common Stock
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		219,000	296,000	267,000
Non-employee director | 2017 Restricted Stock Unit Award Plan | Settlement For Purchase Price
Employee Benefit Plans Disclosure [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period			4,000

LEASES - Additional Information

LEASES - Additional Information (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Lessee, Finance Lease, Description [Abstract]
Lease term	24 months
Finance lease equal monthly payment	$ 3

LEASES - Balance Sheet Informat

LEASES - Balance Sheet Information (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Finance lease right of use (Note 11)	$ 59	$ 0
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Finance lease right of use (Note 11)	Finance lease right of use (Note 11)
Liabilities
Finance lease liability - current	$ 33	$ 0
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Finance lease liability - current	Finance lease liability - current
Finance lease liability - noncurrent	$ 25	$ 0
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Finance lease liability - noncurrent	Finance lease liability - noncurrent
Finance Lease, Liability	$ 58	$ 0

INCOME TAXES - Additional Infor

INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands	Jun. 09, 2021	Sep. 30, 2021
Income Tax Disclosure [Line Items]
Federal NOLs		$ 138,000
Operating Loss Carryforwards, Expiration Term		20 years
Operating Loss Carry Forwards Expiration Year		2037
Tax Credit Carryforward, Amount		$ 150
AD Pharma Amended Agreement | Abuse Deterrent Pharma, LLC
Income Tax Disclosure [Line Items]
Debt Conversion, Original Debt, Amount	$ 6,000
Unpaid interest	$ 877
Principal and interest converted shares	42,984,375

NET INCOME (LOSS) PER SHARE - A

NET INCOME (LOSS) PER SHARE - Additional Information (Details) - $ / shares shares in Millions	Jun. 28, 2019	Sep. 30, 2021	Dec. 31, 2020	Jun. 30, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52	$ 0.01
Schutte Note
Antidilutive Securities Excluded from Computation of Earnings Per Share
Debt Conversion, Converted Instrument, Warrants or Options Issued	10	10
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01	$ 0.01

NET INCOME (LOSS) PER SHARE (De

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net loss per share - basic
Numerator: net loss	$ (262)	$ (678)	$ (908)	$ (965)
Denominator (weighted average):
Common shares	65,089	21,650	40,044	21,650
RSUs - vested	472	686	419	654
Common stock purchase warrants	10,000	10,000	10,000	10,000
Basic weighted average shares outstanding	75,561	32,336	50,464	32,304
Basic net loss per share	$ 0	$ (0.02)	$ (0.02)	$ (0.03)
Net loss per share - assuming dilution
Numerator: net loss	$ (262)	$ (678)	$ (908)	$ (965)
Denominator (weighted average):
Common shares	65,089	21,650	40,044	21,650
RSUs	472	686	419	654
Common stock purchase warrants	10,000	10,000	10,000	10,000
Diluted weighted average shares outstanding	75,561	32,336	50,464	32,304
Diluted net loss per share	$ 0	$ (0.02)	$ (0.02)	$ (0.03)
Excluded securities (non-weighted):
Total excluded potentially dilutive shares	3,091	40,807	3,091	40,807
Restricted Stock Units (RSUs)
Excluded securities (non-weighted):
Total excluded potentially dilutive shares	147	121	147	121
Stock option awards
Excluded securities (non-weighted):
Total excluded potentially dilutive shares	1,162	1,344	1,162	1,344
Common stock purchase warrants
Excluded securities (non-weighted):
Total excluded potentially dilutive shares	1,782	1,842	1,782	1,842
Convertible loan
Excluded securities (non-weighted):
Total excluded potentially dilutive shares	0	37,500		37,500

SUBSEQUENT EVENTS - Additional

SUBSEQUENT EVENTS - Additional Information (Details) - USD ($) $ in Thousands	Jun. 28, 2019	Oct. 09, 2015	Nov. 30, 2021	Oct. 31, 2021	Apr. 29, 2020	Jul. 31, 2021	Mar. 16, 2021
SUBSEQUENT EVENT
Monthly license fees		$ 5,000
2nd PPP Loan
SUBSEQUENT EVENT
Face amount of debt							$ 266
AD Pharma Amended Agreement
SUBSEQUENT EVENT
Monthly license fees	$ 350				$ 350	$ 200
Subsequent event | 2nd PPP Loan
SUBSEQUENT EVENT
Face amount of debt				$ 266
Subsequent event | AD Pharma Amended Agreement
SUBSEQUENT EVENT
Monthly license fees			$ 400	$ 350